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Abstract
Alzheimer’s disease and related dementia (ADRD) rates are expected to triple by the year
2050. Early detection and specific mitigation efforts are warranted to blunt the alarming rate.
Physical function (PF) declines with age, but higher physical function is associated with better
cognitive functioning in middle-to- older age individuals. Moreover, greater physical activity
(PA) is associated with better global cognition; however, Apoliporotein e4 carriers may not gain
the same benefits with exercise. Additionally, plasma phosphorylated tau 217 (p-tau217) has
been identified as a novel diagnostic ADRD biomarker which needs further research to examine
associations with risk factors. Therefore, the aims of this investigation were (1) Understand if
higher physical function clusters produce better cognitive outcomes and blood biomarker profiles
compared to lower functioning clusters among at-risk individuals, (2) Evaluate the ApoE gene’s
mitigating effect on physical activity and blood biomarkers, (3) Examine the associations
between risk factors and p-tau217. Participants (n=216;73.1% female; 45-75years) enrolled in
the study and completed a DXA scan, venous blood draw, RBANS, handgrip, sit-to-stand power
with tendo, dual-task (4-meter and 10-meter), 6-minute walk distance test, nine behavioral risk
surveys, and 6 digital cognitive tests. A hierarchal cluster analysis was utilized to identify PF
cluster for participants, a one-way ANCOVA was used to assess differences in cognition among
clusters. A 2x2 factorial ANCOVA to examine interactions between PA and genetics. A multiple
linear regression was used to evaluate risk factors (independent variables) on p-tau217
(dependent variable). Cluster 1 (C1; n =29) was characterized with the highest strength, power,
faster dual-task walking time, and higher aerobic capacity, Cluster 3 (C3; n =113) had the lowest
values among PF variables, Cluster 2 (C3; n = 74) was in-between C1 and C3. C1 had
significantly higher global cognitive, visuospatial scores, digital executive functioning and
associative learning compared to C2 (p < 0.05). C3 and C1 had significantly higher values on

line orientation task and figure recall than C2 (p < 0.05). Moreover, physically active ApoE
carriers had lower body mass index scores compared to physically inactive carriers where the
opposite was seen among non-carriers (p < 0.05). Lastly, the regression model accounted for
84% of the variance for p-tau217 (p = .01), SF-12 accounted for 9% of that model as the only
significant predictor (p < 0.05). The results from this current study demonstrate that individuals
with higher physical functioning output among clustered variables have higher global cognitive
scores than individuals with lower physical functioning output, lower BMI scores were found
among physically active ApoE carriers, and quality of life may be directly linked to ptau217.
Examining physical functioning variables together may be a valuable tool when assessing
cognitive decline among at-risk individuals. However, larger sample sizes and longitudinal data
is needed to substantiate these claims.
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Chapter 1: Introduction
The rates of Alzheimer’s disease (AD) and dementia are steadily rising with the aging
population increasing. As of 2018, approximately 5.7 million Americans were diagnosed with
AD with an additional person being diagnosed every 65 seconds (Alzheimer’s Association,
2018). Furthermore, AD is the sixth leading cause of death and responsible for more than 80,000
deaths annually in the United States (US) (Alzheimer’s Association, 2015). The rise in rates of
AD coupled with the increasing number of older adults is a major contributor to increased longterm healthcare costs in the US. As a result, early detection and tracking brain health in the aging
population is important more now than ever. The earlier brain health decline is detected, the
more likely clinicians can implement programs to improve modifiable risk factors. One
modifiable risk factor is exercise. The improvement and maintenance of aerobic fitness in an atrisk population may be able to offset declines in brain health scores (memory and processing),
increase cerebral blood flow, and maintenance of brain volume (Bugg & Head, 2011; KirkSanchez & McGough, 2013). Moreover, muscular fitness has been shown to improve brain
function through the upregulation of BDNF through induced IGF-1 levels; higher muscular
36

fitness is associated with higher processing speed and executive function (Herold et al., 2019;
Törpel et al., 2018). The combination of these two components of physical fitness may tell a
greater story about an individual’s cognitive function than one component. However, genetics
play a role in cognitive decline; specifically, Apolipoprotein E (ApoE), possibly hindering some
of the benefits from exercise.
ApoE main role is the regulation of cholesterol and synthesis and distribution which
helps synaptic function maintenance(Huebbe et al., 2007). There are three different forms of
ApoE (e2, e3, e4), the Apo e4 isoform is a non-modifiable risk factor of Alzheimer’s and related
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dementia (ADRD) (Huebbe et al., 2007; Prince, 2018). A person who inherits one ApoE ε4
alleles has 3x the likelihood of developing AD compared to inheriting an ApoE3 allele
(Holtzman et al., 2012). Inheriting two ApoE ε4 alleles increases the risk of developing ADRD
by eight to twelve-fold (Holtzman et al., 2012; Loy et al., 2014; Michaelson, 2014). Currently,
equivocal evidence exists that shows exercise may overcome the ApoE ε4 genetic risk of
Alzheimer’s and some literature contradicts those claims (Colovati et al., 2021; Stringa et al.,
2020). While there is no consensus whether exercise can overcome the genetic risk, there is
plenty of literature that shows the overwhelming cognitive benefits.
While providing exercise as an intervention is a useful method to curb cognitive decline,
better techniques to capture early cognitive decline are needed. Most common methods are
standard cognitive batteries which detect mild cognitive impairment and dementia after the onset
(Alzheimer’s Association, 2019). Moreover, MRIs, PET scans, cerebral spinal fluid taps are an
expensive and invasive techniques examining cognitive decline. Recently, venous blood draws
examining phosphrolyated tau 217 (p-tau217) have been just as strong as common other
biomarkers such as CSF beta amyloid and neurofilament light, and has shown higher accuracy
than p-tau181 (a valid CSF marker) (Mattsson-Carlgren et al., 2020; Palmqvist et al., 2020,
2021). More research is needed to examine what risk factors are correlated with this marker to
help practitioners target certain health issues in curbing cognitive decline in early interventions.
While interventions increasing physical activity and exercise have improved cognitive
outcomes in high-risk individuals; it remains to be seen whether high physical function at
baseline, despite multiple risk factors, produce better cognitive domain scores in high-risk
individuals. Physical function decline later in life is linked to cognitive decline; but physical
function variables clustered together has not been examined. Understanding whether physical
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function clusters can delineate cognitive ability among clusters before noticeable decline may
provide health care professionals time and cost-efficient method of evaluating cognition.
Moreover, ApoE ε4 cognitive decline risk on high-risk individuals with higher physical activity
remains equivocal. It is important to identify whether physical activity can mitigate specific
genetic risk. Lastly, human plasma p-tau217 has been identified as an accurate novel diagnostic
marker of ADRD. However, associations with behavioral and metabolic risk factors have not
been examined among at-risk individuals. Therefore, the purposes of this investigation: (1a).
Understand if higher physical function clusters produce better cognitive outcomes among highrisk, (1b) Examine if higher physical function clusters effect blood biomarker profiles among atrisk individuals, (2) Evaluate the ApoE gene’s mitigating effect on physical activity and blood
biomarkers, (3) Examine the associations between risk factors and p-tau217. Hypothesis 1. I
predict individuals in higher physical function clusters will have better cognitive scores
(memory, learning, language, attention). Also, greater plasma neuroprotective marker levels, and
less cholesterol blood levels when compared to individuals in the lowest physical function
cluster. Hypotheses 2. ApoE ε4 carriers will have lower cognitive outcomes in every physical
activity and exhibit higher neurodegenerative blood levels than non-ApoE ε4 carriers.
Hypothesis 3. Metabolic risk factors and subjective cognitive decline will be associated with
greater likelihood of high p-tau217 plasma concentration.
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Chapter 2: Literature Review
Impact
Alzheimer’s disease (AD) is a developing public health concern in the United States
(Alzheimer’s, 2015; Alzheimer’s Association, 2019; Prince, 2018). As of 2020, approximately 6
million Americans were diagnosed with Alzheimer’s disease or related dementia (ADRD)
(Alzheimer’s Association, 2019). A new diagnosis occurs every 65 seconds, resulting in 1
million new diagnoses each year potentially tripling AD diagnoses by 2050 (Alzheimer’s, 2015).
While average diagnosis of AD occurs at 70 years of age, cognitive decline associated with AD
begins 20-30 years before the onset (Rajan et al., 2015; Wilson et al., 2011). Moreover, AD is
the seventh leading cause of death in the US, and accounts for 121,000 deaths annually
(Alzheimer’s Association, 2019). Since 2000, deaths from heart disease have decreased 14%,
while deaths form AD have increased by 89%. Moreover, AD kills more seniors than breast
cancer and prostate cancer combined, with 1 in 3 seniors dying from Alzheimer’s disease and
related dementias (“2020 Alzheimer’s Disease Facts and Figures,” 2020).
Diseases leading to dementia
Table 1. Diseases and dementia
Disease
Alzheimer’s Disease (AD)

Cebrovascular disease and
vascular dementia (Brenowitz et
al., 2017; Kapasi et al., 2017)

Lewybody disease

Pathology
-Beta-amyloid (plaques)
outside of neurons in
the brain
-protein tau (tangles)
inside neurons
neurodegeneration
-inflammation in brain
and plasma,
-reduced glucose
metabolism
(Alzheimer’s
Association, 2019)
-blood vessel blockage
-damage to areas of
brain tissue or bleeding
in brain
-mixed pathology with
AD is common
Abnormal aggregations
of protein α-synuclein
in neurons (develops in
cortex leading to

Prevalence
60-80% of
cases
(Alzheimer’s
Association,
2019).

Symptoms
Memory deficits: names, recent events or
conversations
-apathy or depression early in
symptomology
Later symptoms:
-diminished communication skills
-disorientation
-confusion
-poor judgement
-behavioral changes
-difficulty speaking, swallowing, walking

8-10% of
cases

-Impaired judgement or ability to make
decisions, plan or organize
-detiortating cognitive and motor function

5-10% of
cases

-sleep disturbances
-well-formed visual hallucinations or
visuospatial impairment
-slowness in gait or imbalances
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Frontotemporal lobar
degeneration

Parkinson’s Disease

Mixed Pathology

dementia with Lewy
Bodies) (Alzheimer’s
Association, 2019)
-Significant atrophy in
frontal and temporal
lobe
-upper layers of cortex
usually are soft, spongy,
and display abnormal
tau pathology or
transactive response
DNA-binding protein
α-synuclein aggregates
in substantia nigra
-aggregates lead to
degeneration in neurons
that specifically
produce dopamine
(Cherubini & WadeMartins, 2018;
Stojkovska et al., 2018)
-Mixture of diseases
leading to mixed
pathology dementia

<10% of
cases but 60%
of cases are
diagnosed in
those 45-60
years of age
(Alzheimer’s
Association,
2019; Prince,
2018)

-Personality behavior and comprehending
decrements early in disease
-Loss of memory later in disease

-uncontrollable shaking
-motor impairment

-multiple
studies
indicate 50%
of AD
dementia
cases
presented
multiple
pathologies
-community
based studies
found >50%
of dementia
cases were
MD
(Brenowitz et
al., 2017; De
Reuck et al.,
2018; James,
2012; Kapasi
et al., 2017)

-Mixture of symptoms

Discrepancy in treatment leading to prevention measures
Currently, the FDA has approved several drug combinations to relieve cognitive
symptoms of AD, but not permitted any drugs to slow the rate of cognitive decline in individuals
at risk for AD. There is no current cure for AD, but delaying the onset of diagnoses by one year
could diminish future pervasiveness by 11% and reduce health care costs by $219 billion
annually in adults 70 and older (Zissimopoulos et al., 2014). Additionally, early detection of AD
can save an estimated $7.9 trillion in medial expenditures, with an estimated $7.0 trillion saved
under a partial early diagnosis projection (Prince, 2018). Early detection for individuals at risk
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for cognitive decline is valuable, allowing for earlier intervention and treatment planning, both of
which can reduce the costs connected with ADRD. The National Institute of AgingAlzheimer’s Association (NIA-AA) and international working group (IWG) proposes three
stages of AD, the first being asymptomatic at-risk individuals (high-risk) exhibiting biomarker
evidence for AD (Prince, 2018). Since the most ideal time to curb cognitive decline is before
noticeable deficits are detected, high-risk individuals should be targeted for multi-domain
interventions. One aspect of multi-domain interventions is physical activity. Higher physical
activity volumes are associated with greater maintenance in different cognitive domains (Barnes
et al., 2003; Barnes, 2015; Cassilhas et al., 2012; Chang et al., 2012).
Physical Activity and Exercise
There is mounting evidence that higher cardiovascular fitness may attenuate cognitive
decline. Aging adults may benefit cognitively from higher cardiovascular fitness through the
increase of cerebral blood flow, as well as structural and functional neuroprotection which could
possibly delay the rate of cognitive decline (Colcombe et al., 2006; Cotman et al., 2007; Kramer
& Erickson, 2007; van Praag et al., 1999). Rodent studies demonstrated that increasing CRF may
stimulate nerve cell growth. This suggests increased CRF provides a neuronal buffer protecting
against neurodegeneration associated with age (Barnes et al., 2003). Moreover, intervention
studies evaluating cognitive functioning and CRF were conducted over multiple years and used
similar cognitive batteries to evaluate cognition. These cognitive tests usually display a learning
effect if taken more than once which may skew results in a longitudinal study design.
While examining cardiovascular fitness, it may be useful separating older adults by physical
activity levels. A recent meta-analysis found that individuals who are more physically active in
midlife and late life have lower risk for global cognitive decline (Kirk-Sanchez & McGough,
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2013). While examining individual sex differences, there is a consensus among lower CRF
levels and poor cognitive health. A longitudinal investigation in men identified participants who
walked <1 mile per day had a 1.7-1.8 fold increased risk for developing ADRD compared to men
who walked >2 miles per day (Kirk-Sanchez & McGough, 2013). Moreover, women in the
Nurses’ Health study, who walked 90 minutes per week demonstrated higher global cognitive
scores than women who walked less than 40 minutes per week (Hagan et al., 2016). Additionally,
lower CRF levels may be attributed to brain atrophy which is noticed in individuals with
dementia. Bugg and Head (2011) found that both low exercisers (0.63 ± 7.4 MET) and high
exercisers (7.8 ± 3.9 MET) displayed brain atrophy in several areas of the brain related to age
(Bugg & Head, 2011). But in subcortical regions, including the medial temporal lobe, age was
correlated with brain volume in the low exercise group but not the high exercise group. Higher
exercise volume may moderate the amount of atrophy in the medial temporal lobe, which is
associated with memory and executive function.
Recently, muscular fitness has been shown to improve brain structure and enhance
certain domains of cognition. Increasing muscular fitness, via resistance training, induces
significant functional brain modifications such as decreased white matter atrophy, smaller white
matter lesion volumes, and increased cortical thickness (Herold et al., 2019; Törpel et al., 2018).
Increased Insulin-like Growth Factor 1 (IGF-1), the mediator of these changes, is associated with
neurogenesis, vascular density, glucose utilization, and synaptic health and memory formation
(Herold et al., 2019; Lichtenwalner et al., 2001; Sonntag et al., 2000; Törpel et al., 2018).
Previous studies suggest that IGF-1 augments synaptic plasticity and neuronal survival
enhancing cognitive performance (Cotman & Berchtold, 2002; Vaynman et al., 2006; adlard,
perreau, cotman, 2005). Moreover, IGF-1 has exhibited the ability to prevent the loss of brain

8
tissue and increase concentrations of brain derived neurotropic factor (BDNF) (Cotman &
Berchtold, 2002). BDNF, found in the central nervous system, mechanistically works in areas
associated with cognitive functioning such as the prefrontal cortex, striatum, hippocampus,
cortex, septum neurons, cerebellum, and motor neurons. These changes in brain structure have
been linked with improvements in processing speed and executive function (Chang et al., 2012).
Muscular strength declines with age which may influence cognition. Aging is a constant
process in which functional, structural, and hemodynamic changes decrease an individual’s
capability to adapt to specific environments, which may induce the onset of pathological
processes, with muscle mass and strength diminishing (Cassilhas et al., 2007; Roubenoff, 2000).
Increases in muscle mass and strength is known to decrease risk for various chronic diseases
while also decreasing anxiety and depression in the aging population. Recently, an 8-year
investigation including 14,000 individuals over the age of 50 examined handgrip strength
(McGrath et al., 2019). Researchers found a 5-kilogram decrease in handgrip strength was
associated with 10% greater odds of cognitive impairment. The loss of muscle mass in the aging
population leads to a weaker grip, but it also may be due to the brain’s ability to direct needed
movement. Required neural and motor functions needed for the grip strength examination could
be compromised when cognitive decline begins (McGrath et al., 2019). Moreover, reduced
handgrip strength has been associated with lower scores in executive function, attention, working
memory, language, semantic fluency, and overall cognition in among non-demented older
individuals (Buchman, Boyle, et al., 2007; Buchman, Wilson, et al., 2007; Guerrero-Berroa et
al., 2014; Rand & Eng, 2011). Recent investigations have found that reduced handgrip strength
at baseline has a high correlation with developing MCI and higher handgrip strength at baseline
may be protective for cognitive function, functional status, mobility, and mortality in adults 60
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and older (Boyle et al., 2010; Rijk et al., 2016). The handgrip test is a global indicator of
muscular strength that is cost-effective and an easily accessible method to identify cognitive
decline, in addition to other validated measures, promoting timely interventions.
Moreover, assessing muscular power in older adults provides a beneficial aspect to
evaluating cognitive decline. While muscular strength is a valuable approach to examining
cognition, muscular power could be more beneficial. Muscular power is a combination of
movement velocity and strength of a particular muscle group. More precisely, lower-extremity
muscular power shows a positive relationship with cognitive outcomes (Cherup et al., 2018;
Gray et al., 2021; Petrella, 2004). Also, interventions aimed to augment muscular power
demonstrated higher executive function scores (Yoon et al., 2017). Moreover, among older
adults, muscular power is more highly associated with cognition compared to muscular strength
(Casas-Herrero et al., 2013; Petrella, 2004), signifying that the velocity of lower-extremity
movement is the most vital facet in the muscular power equation. Additionally, previous
research suggests reductions in neural conduction velocity may contribute to these changes in
muscular power by reducing the ability to move quickly (Palve & Palve, 2018). Testing muscular
power provides a unique method of identifying cognitive impairment due to the incorporation of
velocity providing insight on neural conduction. Higher baseline muscular power production
may prevent further abnormal cognitive decline compared to lower power production. However,
the beneficial effects of physical activity and exercise on the brain may be mitigated by genetics
from person to person.
Apolipoprotein E (ApoE)
ApoE plays an essential role in circulating and central nervous system lipoproteins
metabolism. Majority of production occurs in the brain by astrocytes and to a lesser extent by
microglia and neurons (Huebbe et al., 2007). The key role of ApoE regulation of cholesterol and
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synthesis and distribution which helps synaptic function maintenance. Three isoforms of ApoE
exist (apoE2, apoE3, ApoE ε4 ), the ApoE ε4 isoform is a strong non-modifiable risk factor for
developing AD (Alzheimer’s Association, 2019; Huebbe et al., 2007; Prince, 2018). An
individual inheriting one of the ApoE ε4 alleles has three times the risk of developing AD
compared to an individual who has one ApoE3 allele (Holtzman et al., 2012). Individuals who
inherit two ApoE ε4 alleles have an eight to twelve-fold risk of being diagnosed with AD
(Holtzman et al., 2012; Loy et al., 2014; Michaelson, 2014). Individuals with the e4 form are
more likely to develop AD at a younger age than those with e2 or e3 forms of the ApoE gene
(Spinney, n.d.). A study examining 26 AD centers in the US, found 65% of patients with AD had
at least one copy of the ApoE ε4 gene. Therefore, it is important to evaluate genetic components
in conjunction with physical activity of high-risk populations. While physical activity creates
beneficial cognitive outcomes for aging individuals, ApoE ε4 gene could mitigate positive
changes from physical activity and augment cognitive decline
APOE, Physical Activity, and related biomarkers
Physical activity and exercise are modifiable risk factors for cognitive decline but there is
inconclusive evidence if ApoE mediates the potential positive effect of greater physical activity
rates in individuals who inherit the e4 allele (Colovati et al., 2021; Stringa et al., 2020). A prior
study demonstrated that physically active people who were ApoEe4 carriers showed stable
cognitive functioning and protection against hippocampal atrophy during an 18-month follow up
period compared to physically inactive carriers (Smith et al., 2016). These findings suggest that
greater physical activity levels offer protection against neurodegeneration in ApoE ε4 carriers. In
a recent investigation examining participants older than 65 years (362 carriers and 747 noncarriers), results identified multi-domain interventions were beneficial for cognitive function,
even in patients that were carriers (Solomon et al., 2018). Moreover, another study examining
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1,438 individuals over 6.5 years found that exercise was able to mitigate dementia risk in ApoE
ε4 carriers compared to older adults that were physically inactive (Shih et al., 2018). These
investigations demonstrate physical activity and exercise benefit ApoE ε4 carrier’s cognitive
functioning and structural maintenance of the brain.
However, several studies have failed to detect any effect of physical exercise on individuals
carrying the ApoE ε4 allele (Stringa et al., 2020). One investigation found the likelihood of
developing dementia was not significantly different between ApoE ε4 carriers who exercise and
individuals who do not (Fenesi et al., 2017). Moreover, another study identified that exercise
training did not modify the executive functioning in patients who were carriers (Stern et al.,
2019). Additionally, studies have shown ApoE ε4 carriers have lower plasma concentration of
Brain Derived Neurotropic Factor (BDNF), and exercise training did not improve the levels of
this neurotropic factor (Allard et al., 2017). These studies suggest that exercise does not mitigate
dementia risk, has no effect on executive function, nor neuroprotective blood markers in ApoE
ε4 carriers.
Plasma Phosphophorlated-tau 217 (p-tau217)
Tau is a hallmark pathology in AD and associated with a buildup of senile aβ plaques.
Plasma phosphophoralated-tau217 (p-tau217) has been identified as a potential diagnostic marker
for AD (Mattsson-Carlgren et al., 2020; Palmqvist et al., 2020, 2021). Elevated p-tau217 has
demonstrated a significant relationship with higher brain aβ levels measured by position emission
tomography (Palmqvist et al., 2020). The same investigation found plasma p-tau217 was elevated
among AD patients compared to other patients with tau pathologies and control patients, with a
significantly higher diagnostic accuracy than p-tau181 (current gold standard marker); and similar
diagnostic accuracy as neurofilament light chain and MRI-based biomarkers. Furthermore, a
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longitudinal investigation found elevated plasma p-tau217 in preclinical populations leads to
cognitive decline over time (Mattsson-Carlgren et al., 2020). While p-tau217 shows high accuracy
in predicting cognitive decline, systemic and behavioral factors that contribute to this biomarker
remain scarce. Age, poor diet, obesity, hypertension, diabetes, depression, anxiety, stress, poor
social and cognitive ability, and low physical activity levels all contribute to cognitive decline.
The level of impact that systemic and behavioral factors on plasma p-tau217 levels and the
resulting effect on cognitive decline are unknown.
Metabolic and Systemic Factors
Metabolic and behavioral risk factors have a role in cardiovascular health and cognitive
health (Alzheimer’s Association, 2019; Baumgart, 2015; Cunningham, 2015). Multiple
investigations show age, mid-life obesity, diabetes, and hypertension as strong indicators of
cognitive decline (Beydoun et al., 2008; Biessels et al., 2006; Kivipelto & Solomon, 2006;
Kloppenborg et al., 2008; Loef & Walach, 2013; Lu et al., 2009; McGuinness et al., 2009; Power
et al., 2011; Profenno et al., 2010; Yang & Song, 2013); while high cholesterol has produced mixed
results, and no association with vascular dementia (Anstey & Low, 2008; Kivipelto & Solomon,
2006). Recent evidence suggest statins medications used to lower cholesterol may reduce dementia
(Beri et al., 2009; McGuinness et al., 2009; Muangpaisan et al., 2010); however, evidence is
inconsistent that statins may lower dementia risk (Ligthart et al., 2010; McGuinness et al., 2016;
Richardson et al., 2013). But, metabolic risk (obesity, high blood pressure, and insulin resistance)
are consistently associated with chronic inflammation and higher risk of dementia (alberti et al.,
2006; Farooqui et al., 2011; Nation et al., 2015; St-Onge et al., 2009; van Himbergen et al., 2012).
Several investigations and systemic reviews have shown that mid-life obesity has a strong
association with cognitive decline and an increased risk of dementia (Beydoun et al., 2008;
Kloppenborg et al., 2008; Lee et al., 2010; Loef & Walach, 2013; McGuinness et al., 2016).
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However, with age, being overweight and possibly obese is correlated with a reduced risk of
ADRD (Fitzpatrick et al., 2009; Luchsinger et al., 2007). Moreover, a recent large retrospective
investigation found being underweight had an elevated risk of dementia and lower risk for
individuals overweight at mid-life (Qizilbash et al., 2015). The protective effects of higher BMI
on dementia could be due to low late-life blood pressure, high-later life cholesterol levels, higher
leptin levels, age related changes in metabolism, less likelihood of fragility, increased intake of
vitamin E and vitamin D (Emmerzaal et al., 2014; Qizilbash et al., 2015).
Multiple studies have shown a strong relationship between mid-life high blood pressure
and cognitive decline but an inconsistent relationship between hypertension and dementia (Power
et al., 2011; Sharp et al., 2011). Individuals who have a longer duration of hypertension mid-life
have a greater likelihood of significant cognitive decline. Hypertension is associated with white
matter lesion and impairment of cerebral circulation often leading to ischemic injury (Abell et al.,
2018). RCTs suggest treating hypertension may reduce cognitive decline risk (Chang-Quan et al.,
2011). Additionally later-life hypertension may be neuroprotective similar to obesity, more
research is needed to understand the longitudinal relationship between cognition and hypertension
(Corrada et al., 2017).
Strong evidence persists of diabetes and poor cognitive performance, and a higher risk for
dementia for individuals with diabetes (Biessels et al., 2006; Kloppenborg et al., 2008; Lu et al.,
2009; Profenno et al., 2010). Further evidence shows diabetics with MCI were more likely to
develop ADRD than non-diabetics with MCI (Cooper et al., 2015). Moreover, recent
investigations have shown that diabetes effects dementia risk through other biological/genetic
pathways related to diabetes in addition to vascular pathways (De Felice & Ferreira, 2014; Yang
& Song, 2013). A recent pathway discovered is through the BDNF Val66met, diabetics carrying
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the Val polyporhism usually display lower cognitive output than Met carriers (Zhen et al., 2018).
In older adults, metabolic risk factors are correlated with measurable brain tissue deficits in the
temporal and frontal lobes, the cingulate gyrus, hippocampus and basal ganglia which are areas
most affect by AD related atrophy (Baumgart, 2015).
Moreover, meta-analyses and systematic reviews showed current smoking, traumatic
brain injuries, depression diagnoses, and lack of sleep also increase risk for cognitive decline
(Chang et al., 2013; Diniz et al., 2013; Ju et al., 2014; Lye & Shores, 2000; Rusanen et al., 2011;
Sabia et al., 2012; Wilson et al., 2014; Yaffe, 2012; Yaffe et al., n.d.). Individuals with a history
of depression have a higher likelihood of a dementia diagnoses; while depressive symptoms are
independently associated with poor cognitive performance (Diniz et al., 2013; Yaffe, 2012)(cite).
It is not well understood if depression may augment an individual’s risk or be an early marker of
brain changes correlated with ADRD. Moreover, multiple investigations have displayed that lack
of sleep is associated with cognitive decline (Potvin et al., 2012; Yaffe et al., 2011). Recently,
investigations have shown that tau markers are correlated with a poor sleeping habits compared
to beta-amyloid (Barthélemy et al., 2020).
Conversely, higher education, higher physical activity, socializing, and cognitive
engagement have reduced risk of cognitive decline (Blondell et al., 2014; Fratiglioni et al., 2004;
Sabia et al., 2012; Sofi et al., 2011; Stern, 2012). First, more years of formal education or higher
literacy rate has been shown to reduce dementia risk compared to fewer years of education
(Jefferson et al., 2011; Meng & D’Arcy, 2012). Moreover, socializing has shown protective factor
against abnormal cognitive decline and ADRD (Fratiglioni et al., 2004; Sutin et al., 2020). Some
forms of socializing include joining clubs and engaging in volunteer work; having larger social
networks and history of social contact are correlated with higher cognitive functioning and reduced
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risk for poor cognitive outcomes (Crooks et al., 2008; Noice et al., 2014). But most studies in this
area are combined with physical activity and cognitive training, making it difficult to draw
definitive conclusions (Baumgart, 2015; Cunningham, 2015). Lastly, cognitive engagement and
interventions have displayed effective in improving immediate memory and delayed recall
compared to control groups (Martin et al., 2011). But, due to most interventions being robust in
nature evidence is inconclusive that such cognitive training is solely responsible for improved
outcomes (Stern & Munn, 2009). Additionally, there is substantial evidence that asymptomatic
SCD is correlated with increased likelihood of biomarker abnormalities consistent with AD
pathology and with an increased risk for future cognitive decline and ADRD (Jessen et al., 2014).
However, there is a scarcity of research examining the associations between SCD, position AD
risk factors, and p-tau217. Risk factors associations with the novel biomarker may provide
researchers with future directions to discover potential mechanistic insights to help practitioners
implement protective measures.
Stages leading to dementia

The International Working Group and National Institute on Aging-Alzheimer’s Association
(NIA-AA) propose similar stages of AD development (Figure 1). When examining high-risk
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individuals (potentially stage 1), it is important to examine SCD, risk factors, and biomarkers
before significant cognitive decline is present (stage 2). This proposed project examines highrisk people who are at risk for falling into the AD-continuum beginning at stage 1.
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Chapter 3: Methodology
Participants
This was an exploratory, cross-sectional design where subjects were recruited on a rolling
basis during data collection. We recruited 216 adults (male and female ages 45-75 years) at
increased risk for AD (Table 2). During the visit, participants provided a blood sample, underwent
a body composition analysis, and completed a suite of cognitive, physical and behavioral measures
(described below). Women are at a higher risk for AD than men and also participate in healthbased studies more than men; therefore, may be more interested in this study. We oversampled
men to ensure the sample was representative if necessary but 60% female sample was acceptable.
Inclusion and exclusion criteria are in Table 2.
Table 2. Clinical Trial Inclusion and Exclusion Criteria
Inclusion
•
•
•
•
•

•

•
•
•
•

Age 45-75
BMI 18.5 - 39.9 kg/m2
Fluent in English (written and spoken)
Subjective cognitive decline with worry
A minimum of 2 risk factors for AD on
ANU-ADRI:
• High school education or less
• BMI 25-39.9 kg/m2 (overweight, obese
class I or II)
• History of diabetes • History of
hypertension
• History of high cholesterol • History of
smoking
Maximum of 1 protective factor for AD on
ANU-ADRI:
• High level of physical activity • High fish
consumption
• High level of cognitive engagement
Ability to send and receive text messages
Access to a smartphone or tablet with a
screen-side camera and reliable internet
connection
Ability to participate in light to moderate
physical activity
Willing to authorize release of medical
records

Exclusion

• Physician diagnosis of
• mental health condition (e.g., eating disorder,
alcohol/substance use, schizophrenia, etc.)
• neurologic conditions (e.g., epilepsy, recent stroke,
multiple sclerosis, Parkinson’s disease, brain tumor,
or severe traumatic brain injury)
• dementia, probable dementia, or mild cognitive
impairment
• other significant health condition (e.g., congestive
heart failure, chronic obstructive pulmonary disease,
coronary artery disease, renal failure, chronic kidney
disease, pulmonary hypertension)
• Recent cardiovascular event or treatment for cancer
(within the last year); on dialysis; or on active organ
transplant list
• Visual problems that prevent viewing screen at a normal
distance (e.g., legal blindness, detached retina,
occlusive cataracts)
• History of learning disability
• Currently participating in a cognitive training coaching
program or other lifestyle change program (e.g.,
diabetes prevention program)
• Currently pregnant or planning on becoming pregnant
in the next two years
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Biometric Assessments
Biometric assessments included height, weight, and body composition (fat free mass, fat
mass, bone mineral density). Height was measured with a standing stadiometer (Seca; Hamburg,
Deutschland). During this assessment, participants were asked to remove their shoes and stand
up as straight as possible. Height was recorded to the nearest 0.1 cm. Weight was measured with
a balance-beam scale (Detecto, Webb City, MO). Participants removed their shoes, any heavy
clothing (sweaters, jackets, or coats), and empty their pockets. Weight was measured to the
nearest 0.1 kg. Body composition was measured through a DEXA scan (General Electric
Company, Madison, WI) during the initial visit.
Physical Function
Six-minute Walking Distance Test (6MWDT). The 6MWDT is a field measure of
aerobic capacity which has a high test-retest reliability (ICC = .96), a minimal clinical important
difference (MCID) of 20.0 meters, and stability over time (Teresa, 2002). From a standing start,
participants were instructed to walk continuously for 6 minutes around a 200-meter track, at the
fastest pace they feel they can maintain throughout the duration of the examination. Participants
were told their goal is to cover as much ground as possible in 6 minutes. Participants were
allowed to stop and stand or sit in chair if desire to rest is verbalized and they were instructed to
walk again when they felt able. Distance walked will be recorded at the end of the test. This is a
safe field submaximal aerobic capacity test; the 6MWDT is safer than the forester stepping test
and more indicative of aerobic capacity than the YMCA submaximal bike protocol.
Hand-grip Strength. Hand-grip testing was used as a measure of isometric strength as it
is highly correlated with overall strength and functional independence. All measurements were
administered by a trained technician and measured in kilograms using a handheld dynamometer.
All measurements were performed on each hand with the subject standing, arm down at the side,
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wrist in neutral position, and interphalangeal joint of the index finger maintained at 90 degrees.
Participants were instructed to maximally squeeze the handle for 5 seconds with standard
encouragement provided. The test will be administered 3 times with 60s rest between attempts.
This test has shown high test–retest reliability ICC of 0.95, MCID of 6.5 kg (19.5%) change (Perera
et al., 2006). This strength test is safer for the population in the proposed study compared to one
repetition maximum bench press, leg press, or back squat.
Lower-body Muscular Power. Sit-to-stand power will be measured using the Tendo
Weightlifting Analyzer (Trencin, Slovac Republic). The Tendo will be attached to the side of each
participant by securing a belt around the participant’s waist. To ensure consistency, the Tendo will
be placed on the participant’s left side, with the Kevlar string positioned to be in the sagittal plane,
when the participant is in the standing position. The Tendo will be attached to the participant by
securing a belt around the participant’s waist. From a seated position, with the arms placed across
opposing shoulders, the participant will be instructed to stand as quickly as possible before slowly
returning to the initial seated position (outcome measures only take into account the egress
component of the STS). As the participant stands as quickly as possible, the Tendo’s Kevlar string
is pulled and average/peak power output (W) for each stand is recorded. Five repetitions will be
recorded with a 60-second rest between each repetition. Average power is calculated as the mean
power generated among all 5 repetitions and peak power is determined as the highest power
recorded during any of the 5 repetitions. Average velocity is calculated as the mean velocity
generated among all 5 repetitions and peak velocity is determined as the highest velocity recorded
during any of the 5 repetitions. This measure was validated for use in middle-age and older adults
(Glenn et al., 2015; Gray & Paulson, 2014); MCID of 17% change in average power and 9%

20
change in peak power. This assessment is a safer alternative to Olympic lifts (power clean, hang
power clean, power snatch) examining an at-risk older population.
Dual-task. The dual-task walking assessment evaluated attention and executive function
(Brustio, Magistro, Zecca, Rabaglietti, & Liubicich, 2017; Yogev-Seligmann, Hausdorff, &
Giladi, 2008). This assessment has been described in detail elsewhere (Glenn, Vincenzo,
Canella, Binns, & Gray, 2015). Dual-task assessments vary in protocol, but for the purposes of
this study, participants were instructed to walk 20 meters at their usual speed while time was
recorded by the researcher. There was a 5-meter distance before and after the 10-meter distance
to account for acceleration and deceleration (Glenn et al., 2015). For the next part of the
assessment, participants were instructed to walk as quickly and safely as possible without
running. These two assessments were used as the baseline tests. For the dual-task conditions,
participants were instructed to perform the same walking conditions and simultaneously perform
serial subtractions (Hausdorff et al., 2001). A random 3-digit number between 199 and 999 was
selected and participants were instructed to subtract three from each number while performing
each walking condition. Four testing trials were completed, two at usual speed (dual-task
habitual speed) and two at their maximal speed (dual-task maximal speed). Dual-task decrement
was calculated as the difference between the walk trial while performing serial subtractions and
the trial without subtraction. The walking speed trials (DT-HS and DT-MS) were averaged
separately and used for all analyses. Dual-task is a valid and reliable method for assessing
working memory in young and older adults (Montero-Odasso et al., 2009; McCulloch et al.,
2009).
4-meter dual-task walk. Dual-task assessments vary in protocol, but for the purposes of
this study, participants were instructed to walk 4 meters at their usual speed while time was
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recorded by the researcher. For the next part of the assessment, participants were instructed to walk
as quickly and safely as possible without running. These two assessments were used as the baseline
tests. For the dual-task conditions, participants were instructed to perform the same walking
conditions and simultaneously perform serial subtractions (Hausdorff et al., 2001). A random 3digit number between 199 and 999 was selected and participants were instructed to subtract three
from each number while performing each walking condition. Four testing trials were completed,
two at usual speed (dual-task habitual speed) and two at their maximal speed (dual-task maximal
speed). The walking speed trials (DT-HS and DT-MS) were averaged separately and used for all
analyses. This test is a part of the short physical performance battery that has high test-retest
reliability (Gómez Montes et al., 2013).
Surveys
ANU-ADRI. This is an evidence-based 79-itme risk assessment method to predict the risk
of future AD development. It collection information on age, sex, education, body mass index,
diabetes, depression, serum cholesterol, traumatic brain injury, smoking, alcohol intake, social
engagement, physical activity, cognitive activity, fish intake, and pesticide exposure. This is a
valid and reliable measure (Anstey et al., 2013).
Physical Activity. Physical activity was assessed using the International Physical Activity
Questionnaire (IPAQ), this is a component of the ANU-ADRI. IPAQ is a reliable and valid
subjective tool for quantifying sedentary, moderate, and vigorous behaviors (Craig et al., 2003).
Subjective Cognitive Decline (SCD). Everyday Cognition (ECog-12) 12-item
Assessment was utilized to evaluate subjective cognitive decline. ECog-12 is a self-report measure
of level of independence in performing cognition-based daily tasks. This assessment contains 12
cognition-based questions for individuals to answer 1 (better or no changed compared to 10 years
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ago) through 4 (consistently much worse). This test has been validated and has high test-retest
reliability (Tomaszewski Farias et al., 2011).
Loneliness. The University of California, Los Angeles, 3-item Loneliness Scale was
utilized to examine the degree of loneliness among participants (Hughes et al., 2004). Scores
ranged from 3-9, with higher scores indicating greater levels of loneliness. Scores above 5 indicate
loneliness.
Sleep. Quality of sleep was measured using Pittsburgh Sleep Quality Index. The 9-item
assessment provides a score ranging from 0-27, with higher scores being associated with poor
sleep. Individuals scoring >5 are deemed poor sleepers (Buysse et al., 1989).
Depression. The Patient Health Questionnaire was used to analyze depression, this is a 9item questionnaire with scores ranging from 0-27. Higher scores indicate higher levels of
depression (Martin et al., 2011).
Health-Related Quality of life. The 12-item Short Form Health Survey was used to
evaluate quality of life. This is a valid and reliable measure for health-related quality of life in
various populations (Ware, Kosinski, and Keller, 1996 ). There are two subscales: physical health
and mental health. Scores range from 12-47, with higher scores associated with higher selfreported quality of life.
Anxiety. Anxiety was measured using the General Anxiety Disorder 7-item scale (Spitzer
et al., 2006). This measure is valid and reliable anxiety tool among older adults (Löwe et al., 2008).
Scores range from 0 to 21, with higher scores indicating higher anxiety severity.
Perceived Stress. Perceived stress was analyzed using the Perceived Stress Scale (Cohen
et al., 1983). Scores ranged from 0-40, with lower scores related to lower perceived stress. Scores
0-12 show low stress, 14-26 indicates moderate stress, and >26 display high stress.
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Asynchronous Cognitive Testing Battery
Image Pairs. Image Pairs is an eye tracking-based task that measures visual recognition
memory and learning (Bott et al., 2018; Gills et al., 2019, 2020). The visual paired comparison
portion of the test measured the participant’s ability to recognize images they have already
viewed during a familiarization phase. The paired recognition trial portion of the test measured
the participant’s ability to learn and identify image pairs they have been tasked with learning.
Symbol Match. Symbol Match is a processing speed and executive functioning task that
utilizes a paired verification or rejection paradigm (forced choice). Participants were instructed
to determine whether two symbols are equal or unequal utilizing a legend with nine
number/symbol pairs. At the conclusion of the task, a brief implicit learning trial was
administered without the legend present.
Arrow Match. The Arrow Match test is a measure of attention and processing speed.
Participants were shown five arrows in the middle of the screen and were instructed to identify
the direction of the middle arrow. The arrows can point in either the same direction or in the
opposite direction from the other arrows. Participants were presented with 32 trials and scores
are reported as the number of correct responses relative to the time elapsed during all trials.
Item Price. Item Price is a brief visual paired associates paradigm. This task required
participants to learn eight food/price pairs and discriminate between target and foil (items
previously present but not paired) pairs during a recognition trial. All items belong to the same
semantic category (fruits, vegetables, etc.) and are presented in pseudorandom order using a
blocking scheme.
Path Points. Executive function is assessed using the Path Points test. Similar to the
paper-pencil Trail Making Test Part B (Lezak, 1995), Path Points is a digital version where
participants connected a series of alternating numbers and letters from 1-A to 7-G. Scores were
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reported as the amount of time required to complete the 14 responses. Only correct responses
are allowed.
Light Reaction. Reaction time and inhibition are assessed with the Light Reaction test.
Participants were presented with either a positive stimulus (green light) or negative stimulus (red
light). If the positive stimulus appears, they were tasked with pressing a button. If the negative
stimulus appears, they were tasked with refraining from pressing the button. Average response
time for reacting to the positive stimulus (green light) was recorded.
RBANS Cognitive Assessment
Each participant was individually administered the RBANS assessment (RBANS; Forms
A, B & C). The RBANS assessment was completed on an iPad along with paper and pencil. The
RBANS assessment construction is explained in detail elsewhere (Dickerson et al.,
2004). Briefly, the RBANS is made up of 12 subtests that are used to calculate five index scores
and a total score. Test catalogues include: Immediate memory (list learning and story memory
tasks), Visuospatial/constructional (comprised of figure comply and orientation tasks), language
(picture naming and semantic fluency tasks), attention (digit span and coding tasks), and delayed
memory (list recall, story recall, figure recall, and list recognition tasks). Each index score falls
within an age-adjusted score (Dickerson et al., 2004). The index scores are combined to produce
a total score, which is a summary score of the participant’s performance on the RBANS. The
RBANS test took approximately 30 minutes to administer and complete. Previous research
showed the RBANS is significantly correlated with more extensive exams such as the Wechsler
Adult Intelligence Scale III and the Wechsler Memory Scale III, it also has strong test-retest
reliability (Hobart & Bartko, 1999; Wilk et al., 2002).
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Venous Blood Draw
To evaluate biomarkers (p-tau217, ApoE, cholesterol, and glucose), a venous blood draw
was taken at the beginning of the visit (subjects were on a 3-hour fast). Samples was stored at 800 C until analysis. P-tau217 was analyzed using enzyme-linked immunosorbent assays (ELISA)
kits following instructions provided by manufacturers. Genetic testing through real time PCR was
completed to asses ApoE ε4 in as an additional risk factor for AD. Cholesterol and glucose was
examined through Cholestech (Stat-technolgies, Golden Valley, MN). ApoE will be analyzed by
a third party laboratory.
SNP Genotyping
DNA was extracted from participant’s whole blood. ApoE alleles were observed through
SNPs rs7412 and rs429358 that were genotyped using real time PCR for 215 participants by a third
party (CD Genomics, Inc., Shirley, NY). e2 genotype was determined by T for a SNP rs7412 and
T on SNP rs429358, e3 genotype was determined by C for a SNP rs7412 and T on SNP rs429358,
e4 genotype was determined by C for a SNP rs7412 and C on SNP rs429358 (Sebastiani et al.,
2019).
Statistical Analysis
All data was inspected to identify missing items and outliers. Conclusions were formed
that are robust to different missing-data mechanisms (Raudenbush & Bryk, 2002). All data was
subjected to quality control checks prior to proposed statistical analysis (e.g., homogeneity,
multicollinearity). Assumptions for regressions and ANOVA were assessed including linearity,
independence of error, homoscedasticity, heterogeneity, independence, and normality.
Demographic and efficacy data was summarized by mean ± SD. Summary tables of continuous
variables will present arithmetic mean, 95% CI, and SE. Summary tables of categorical
variables will present counts and percentages. Hypothesis testing was carried out at the 5% (2sided) significance level unless otherwise specified, and P-values was rounded to three decimal
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places. SPSS (version 26) was used for descriptive calculations, ANOVA comparisons, and
regression modeling.
Sample size and power calculation: Based on power analysis in G power to document that we
have a sufficient sample size, we anticipated exceeding 95% power to detect meaningful
associations between proposed variables during linear regressions and delineate differences in
ANOVA. Power may decrease when looking at the differences between clusters and physical
activity/genetic groups due to unequal and lower sample sizes. However, it is still important to
understand which metabolic and behavioral factors affect cognition the most.
Question 1: A hierarchical cluster analysis was utilized to identify profiles based physical
function levels among participants. A K-means cluster analysis was used to place participants in
three clusters determined by the hierarchical cluster analysis. Physical function (Sit-to stand power
variables, handgrip, 6MWDT, 4m fast, 10fast, 4mDTHab, 4mDTfast, 10mDThab, 10mDTfast)
cluster individuals into specific clusters based on physical function scores. A one-way ANCOVA
determined the differences in cognitive domain scores and blood biomarkers among each physical
activity cluster. Age (not controlled for in digital cognitive tasks), sex, education, and APOE were
co-variates in the model.
Question 2: iPAQ data was separated by top 50% and bottom50%. A 2x2 factorial ANCOVA was
used to examine whether ApoE ε4 (carrier and non-carrier) mitigates PA (top 50%, bottom 50%)
changes in cognition and blood biomarkers among each cluster and across clusters. Age, sex,
education, and APOE were co-variates in the model.
Question 3: I used multiple linear regressions using age, education, sex, Ecog-12, metabolic and
behavioral factors as predictor variables; and p-tau217 as the dependent variables. Independent
variables in regressions: age, education, sex, BMI, glucose, HDL, LDL, blood pressure, physical
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activity levels, SCD, triglycerides, depression, and social engagement. Dependent variables in
regressions: P-tau 217.
Chapter 4: Results
Demographic information
Of the 216 subjects that completed the study, the mean age was 59.7 ± 14.1 years, 73.1%
female (158 participants), and 97% Caucasian Americans represented the sample; additionally,
participants had an average educational years in school of 17.9 ± 3.5 years. Participant’s
biometric information included: weight of 84.1 ± 19.9 kilograms, height of 165.9 ± 18.4
centimeters, and body mass index (BMI) of 30.1 ± 5.2 kg/m2.
Physical Function Clusters
Based on the observed changes of the agglomeration schedule, a 3-cluster solution could
best discriminate between measures of physical function and produce satisfactory division of
individuals between clusters and was, therefore, selected for the subsequent analysis.
Cluster 1 (C1; n = 29) is characterized by high overall strength, power, faster dual-task walking
time, and higher aerobic capacity. Cluster 3 (C3; n = 112) is described as the lowest strength,
lower power output, slower dual task times and lowest aerobic capacity. Cluster 2 (C3; n = 74) is
in-between clusters 1 and 3 for all values (Table 3). A posteri observed power for significant
variables ranged from 0.65-0.93.
Table 3. Cluster centers
Cluster1 (n = 29)

Cluster 2 (n = 74)

Cluster 3 (n = 113)

p –value

HG Right (kg)

37.99

31.66

26.61

< .001

HG Left (kg)

34.87

30.34

25.23

< .001

Average Power (W)

659.38

499.22

336.32

< .001

Average partial power (W)

548.16

421.54

296.59

< .001

Peak Power Average (W)

1508.42

1020.01

632.97

< .001

Cluster1 (n = 29)

Cluster 2 (n = 74)

Cluster 3 (n = 113)

p –value
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Average Velocity (m/s)

0.68

0.58

0.46

< .001

Peak Velocity (m/s)

1.16

0.99

0.77

< .001

Peak Force (N)

1504.19

1213.62

933.29

< .001

4m Fast (s)

2.16

2.32

2.40

.022

10m Fast (s)

4.94

5.35

5.63

.005

4 m DT Hab (s)

21.10

3.58

3.81

.043

4m DT Fast (s)

28.63

2.66

2.93

.041

10m DT hab (s)

7.87

8.30

9.11

.012

10m DT fast (s)

5.82

6.16

6.81

< .001

6MWDT (m)

566.8

546.6

517.6

.002

Note. Cluster means, HG=hand grip, DT= dual task, hab= habitual, m=meter

Cognitive scores. Significant differences were exhibited among global cognitive scores
(RBANS total score) (F (2,198) = 3.73, p = .026; η2p =.036; figure 2, Table 4), C1 performed
significantly better on RBANS than C3 (p = .021; figure 2). Visuospatial scores showed
significant differences among groups (F (2,198) = 5.66, p = .004; η2p =.054; figure 3); C1
performed significantly better on this task than C3 (p = .006; Table 4). Line orientation, a
visuospatial test, scores were significantly different between groups (F (2,197) = 3.73, p = .001,
η2p =.068; Table 4); C1 had significantly higher scores compared to C3 (p = .004) and C2
performed significantly better than C3 (p = .008). Furthermore, the figure recall exam, a delayed
memory test, showed significant differences between groups (F (2,197) = 4.87, p = .012; η2p
=.044; Table 4). C1 performed significantly better than C3 (p = .011). A significant trend was
noticed between clusters for attention domains (F (2,198) = 2.78, p = .065; η2p =.027; Table 4).
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Table 4. Cluster cognitive domain data
Cluster 1 (n = 29)
Immediate Memory
105.0 ± 2.0

Cluster 2 (n = 74)
100.7 ± 1.6

Cluster 3 (n = 113)
102.7 ± 1.3

p-value
.137

Visuospatial/constructional

108.3 ± 2.7*

102.3± 1.7

97.8 ± 1.5*

.031

Language

100.8 ± 2.3

102.7 ± 1.1

102.1 ± 1.0

.224

Attention

115.1 ± 2.4

111.1 ± 1.5

108.2 ± 1.3

.264

Delayed Memory

105.9 ± 1.5

112.9 ± 9.0

102.7 ± 1.3

.249
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Total Score

Cluster 1 (n = 29)
109.0 ± 2.1*

Cluster 2 (n = 74)
104.3 ± 1.9

Cluster 3 (n = 113)
103.8 ± 1.1*

p-value
.026

Note. Mean ± SE

Among the digital cognitive tasks, there was a difference in path points (executive
function) scores (F (2,190) = 6.05, p = .003; η2p =.06; Figure 4). C1 performed significantly
better than C3 (p = .018), C2 also had significantly higher scores than C3 (p = .013). Moreover,
significant differences were identified among the Item Price (associative learning) task (F
(2,185) = 3.54, p = .031; η2p =.04; Figure 5). C1 performed significantly better than C3 (p =
.044). No other significant differences were found between each cluster during the digital
cognitive task.
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Table 5. Cluster individual exam cognitive data
Cluster 1 (n =
29)

Cluster 2 (n =
74)

Cluster 3 (n =
113)

p-value

Listen Learning (IM)

28.9 ± 0.7

28.1 ± 0.5

28.0 ± 0.4

.337

Story Memory (IM)

18.9 ± 0.5

17.7± 0.4

18.1 ± 0.3

.236

Figure Copy (V/C)

18.6 ± 0.4

18.1 ± 0.2

17.9 ± 1.0

.274

Line Orientation (V/C)

17.9 ± 0.4a

16.9 ± 0.3b

15.8 ± 0.3a,b

.001

Semantic Fluency (LAN)

21.9 ± 1.0

22.3 ± 0.5

21.9 ± 0.4

.266

Picture Naming (LAN)

9.7 ± 0.1

9.8 ± 0.1

9.6 ± 0.1

.283

Coding (ATT)

52.0 ± 1.3

49.7 ± 0.9

48.3 ± 0.9

.171

Digit Span (ATT)

13.0 ± 0.5

12.2 ± 0.4

11.6 ± 0.4

.201

List recall (DM)

6.3 ± 0.3

6.7 ± 0.2

6.6 ± 0.2

.836

Story Recall (DM)

9.9 ± 0.3

9.6 ± 0.2

9.6 ± 0.2

.582

Figure Recall (DM)

15.9 ± 0.5*

14.3 ± 0.4

13.1 ± 0.4*

.012

List Recognition (DM)

19.5 ± 0.2

19.3 ± 0.1

19.5 ± 0.1

.370

Arrow Match (attention)

37.5 ± 4.5

33.9 ± 3.0

32.3 ± 2.6

.726

a

b

a,b

Path Points (Exec Func)

70.9 ± 6.0

66.1 ± 3.4

55.4 ± 3.0

.003

Light Reaction (Inhibition)

27.2 ± 4.5

29.1 ± 3.5

24.9 ± 2.5

.208

Symbol Match(Processing sp.)

40.0 ± 5.7

38.9 ± 3.1

37.2 ± 2.9

.339

*

*

Item Price (As. Learning)

60.7 ± 4.9

53.8 ± 2.8

47.4 ± 2.7

.031

Paired imaging (As. Memory)

40.3 ± 5.9

44.4 ± 4.1

46.6 ± 3.1

.920

Note. Mean ± SE, IM = Immediate memory, V/C = visuospatial/constructional, LAN = Language,
ATT = Attention DM = delayed memory, Exec Func = executive functioning, processing sp. =
processing speed, As. = associative.
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Metabolic and Blood Biomarkers. There were no significant differences between
clusters for total cholesterol, LDL, TC/HDL, HDL TRG, glucose, resting HR, blood pressure
data, or BMI (p > 0.05; Table 6).
Table 6. Cluster metabolic data
Cluster 1 (n = 29)

Cluster 2 (n = 74)

Cluster 3 (n = 113)

p-value

Age

56.9 ± 8.2

60.5 ± 8.0

64.2 ± 7.6

<.001

Sex (female%)

37.9

66.2

86.7

<.001

Weight

96.9 ± 23.2

89.7 ± 17.5

78.6 ± 14.6

.009

Height

174.7 ± 9.1

170.3 ± 9.0

163.8 ± 7.4

.002

BMI

31.5 ± 5.8

30.9 ± 5.7

29.1 ± 4.6

.090

Education

18.1 ± 2.8

17.9 ± 3.3

17.8 ± 4.2

.922

Resting SBP

126.0 ± 11.4

128.1 ± 10.8

128.6 ± 13.2

.608

Resting DBP

81.6 ± 9.5

82.3 ± 10.1

82.1 ± 10.4

.958

Resting HR

73.6 ± 14.5

71.2 ± 12.6

72.6 ± 9.6

.586

Total Cholesterol

199.5 ± 45.6

201.7 ± 41.9

204.9 ± 43.3

.142

LDL

118.9 ± 35.7

120.9 ± 33.9

122.8 ± 48.2

.906

HDL

50.4 ± .18.2

53.7 ± 17.8

59.4 ± 14.8

.704

TRG

159.7 ± 121.0

134.1 ± 66.9

136.7 ± 66.2

.308

Fasting Glucose

99.6 ± 14.8

106.5 ± 24.3

100.7 ± 21.7

.168

Note. Mean ± SD, BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood
Pressure, LDL = Low density lipoprotein, HDL = High density lipoprotein, TRG = Triglyceride

Physical Activity and ApoE differences
Since there were only two ApoE ε4 carriers in the C1, carriers and non-carriers
differences were analyzed through subjective IPAQ data (top 50% and bottom50% based on the
median of 4450MET per minute). Observed power for significant variables ranged from .53-.79.
Metabolic and blood biomarker data. BMI had a significant interaction effect between
ApoE and physical activity groups (F(1,198) = 4.01, p = .047; η2p =.02). ApoE carriers that were
physically active individuals had lower BMI compared to the physically inactive individuals
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(Table 7). However, the ApoE non-carriers who were physically inactive had lower BMI
compared to the physically active group. Moreover, a significant trend was identified in
triglycerides non-carriers who were physically active had higher triglycerides than physically
inactive but ApoE carriers who were physically active had lower triglyceride levels than
physically inactive individuals (F(1,192) = 3.25, p = .073; η2p =.02; Table 7). The high physical
activity group showed significantly higher resting heart rates compared to low physical activity
group (F(1,198) = 4.87, p = .028; η2p =.02; Table 7). In addition, carriers had significantly lower
resting HR than non-carriers (F(1,198) = 6.23, p = .013; η2p =.01; Table 7). No other differences
were found in metabolic and blood biomarker data between ApoE carriers and non-carriers or
physical activity groups (p > .05).
Table 7. Metabolic and blood profiles of ApoE and physical activity levels
ApoE ε4 carriers
ApoE ε4 non-carriers
PA (n = 32)

PIA (n = 20)

PA (n = 72)

PIA (n = 79)

p-value

Age

61.6 ± 1.5

60.6 ± 1.8

62.6 ± 0.9

62.0 ± 0.9

.860

Education

16.1 ± 0.6

18.3 ± 0.7

17.9 ± 0.4

18.7 ± 0.4

.215

BMI

28.0 ± 0.9

30.7 ± 1.1

30.6 ± 0.6

30.0 ± 0.6

.047

Resting SBP

130.4 ± 2.1

126.7 ± 2.5

129.0 ± 1.3

126.3 ± 1.3

.799

Resting DBP

82.8 ± 1.8

80.1 ± 2.2

83.2 ± 1.2

81.2 ± 1.2

.818

Resting HR

65.6 ± 1.9

71.9 ± 2.3

72.4 ± 1.2

73.6 ± 1.2

.131

Total Cholesterol

209.1 ± 7.8

194.8 ± 9.4

201.7 ± 9.4

203.4 ± 4.9

.256

LDL

128.1 ± 7.9

120.3 ± 9.8

117.8 ± 5.3

123.1 ± 4.9

.362

HDL

56.6 ± 2.8

51.9 ± 3.4

56.5 ± 1.8

57.3 ± 1.8

.286

TRG

118.1 ± 13.4

148.9 ± 16.6

147.8 ± 9.0

134.4 ± 8.5

.073

Fasting Glucose

99.4 ± 3.9

102.1 ± 4.8

100.7 ± 2.6

104.8 ± 2.5

.845

Note. Mean ± SE, SBP = systolic blood pressure, DBP = diastolic blood pressure, HR = heart rate, PA
= physically active, PIA = physically inactive

Cognition. Physically inactive showed higher RBANS scores than physically active
(F(1,196) = 4.53, p = .034; η2p =.023). ApoE carriers had significantly higher language scores
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than non-carriers (F(1,196) = 5.79, p = .0.017; η2p =.006). No significant differences were
found between carriers and non-carriers or physical activity groups among remaining RBANS
domain and individual test scores (p > .05; Table 8).
In the digital cognitive test, results showed that physically inactive individuals had
significantly higher associative learning scores than physically active (F(1,183) = 7.82, p =
.0.006; η2p =.041). Moreover, a significant trend was found in the associative memory task
(F(1,123) = 3.74, p = .055), ApoE non-carriers showed better scores than carriers. No other
significant differences were found for the remaining four digital cognitive tests (p > .05; Table
8).
Table 8. Cognitive scores of ApoE and physical activity levels
ApoE ε4 carriers

ApoE ε4 non-carriers

PA (n = 32)

PIA (n = 20)

PA (n = 72)

PIA (n = 79)

p-value

Immediate Memory

99.7 ± 2.3

105.8 ± 2.8

101.5 ± 1.5

102.7 ± 1.4

.229

Visuospatial/Constr.

103.7 ± 2.9

103.9 ± 3.6

99.1 ± 1.9

100.0 ± 1.8

.889

Language

104.0 ± 1.7

106.6 ± 2.1

102.3 ± 1.1

100.0 ± 1.7

.181

Attention

109.6 ± 2.4

104.0 ± 1.7

110.1 ± 1.6

109.9 ± 1.5

.289

Delayed Memory

105.7 ± 8.5

99.9 ± 10.6

103.7 ± 5.6

112.2 ± 5.4

.361

Total Score

101.8 ± 2.3

110.2 ± 2.9

104.2 ± 1.5

104.9 ± 1.5

.073

Arrow Match (ATT)

29.2 ± 4.7

33.4 ± 5.7

35.3 ± 3.1

31.7 ± 2.9

.360

Path Points (Exec. Func.)

59.0 ± 5.5

63.7 ± 6.9

63.2 ± 3.6

58.2 ± 3.6

.343

Light Reaction (Inhibition)

20.3 ± 4.9

28.4 ± 5.8

28.9 ± 3.1

25.4 ± 3.1

.189

Symbol Match(Processing sp.)

31.1 ± 5.3

42.9 ± 6.4

38.1 ± 3.4

39.6 ± 3.3

.283

Item Price (As. Learning)

46.2 ± 4.8

62.8 ± 6.1

46.6 ± 3.1

55.4 ±

.379

Paired imaging (As. Memory)

28.9 ± 6.1

45.2 ± 7.6

45.7 ± 3.8

49.6 ± 3.7

.271

Note. Mean ± SE, ATT = Attention, Exec Func = executive functioning, processing sp. = processing
speed, As. = associative.

P-tau217 Associations
The model used explained 55% of the variance for p-tau217 but was not significant (F
(20,7) = 2.65; p = .095). Moreover, BMI (r = .42; p = .013), gender (r = .35; p = .033) were the
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only significant correlations with p-tau217. However, this model had multi-collinearity issues
with perceived stress and resting DBP being the highest; and HDL and LDL overlapping with
total cholesterol. So, a second model was created to resolve the multi-collinearity issues.
The second model explained 49% of the variance for p-tau217 but was not significant (F
(17, 10) = 7.90; p = .068). Again, BMI (r = .42; p = .013), gender (r = .35; p = .033) were the
only significant associations with p-tau217.
These models are underpowered due to the lack of p-tau217 data due to the ELISA kit
detection range being too high to identify the amount of protein in all samples (28 samples were
detected and used in this analysis).
Table 9. Descriptive statistics for AIM 3
N

Mean

Age (years)

26

62.5 ± 0.6

Sex (female)

26

58%

Height (cm)

26

170.2 ± 10.5

Weight (kg)

26

83.9 ± 19.1

Education (years)

26

18.4 ± 4.5

Note. Mean ± SD
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Table 10. The relationship between risk factors and p-tau217 in at-risk individuals
Dependent variable: p-tau217 concentration (ng/mL)
Model 1
Predictors

Model 2

Estimate (B)

LL 95% CI

UL 95% CI

Estimate (B)

LL 95% CI

UL 95% CI

Age

0.45

-1.64

7.1

0.24

-2.38

5.26

Gender

0.44

-17.74

113.07

0.32

-25.17

94.80

-0.39

-18.32

4.50

-0.24

-13.88

5.59

ApoE

-0.54*

-114.05

-2.76

-0.64*

-122.50

-15.10

Physical Function

-0.57*

-81.17

-2.83

-0.67*

-85.95

-12.85

QoL

-0.48

-13.71

3.38

-0.62

-14.58

1.34

Sleep

-0.67*

-28.57

-1.10

-0.38

-19.52

2.82

0.02

-11.07

11.70

0.30

-4.92

15.07

Depression

-0.99*

-28.57

-4.21

-0.99

-28.41

-4.60

Loneliness

0.07

-12.64

17.92

0.08

-11.42

17.09

-.027

-9.01

2.62

-0.21

-8.26

3.21

Education

Anxiety

Subjective Cog. Dec.
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Model 1
Predictors

Model 2

Estimate (B)

LL 95% CI

UL 95% CI

Estimate (B)

LL 95% CI

UL 95% CI

0.12

-3.82

2.45

0.40

-0.26

7.09

-0.17

-3.83

2.45

0.13

-1.23

2.31

TRG

0.20

-0.24

0.61

0.09

-0.29

0.48

GLU

0.41

-0.38

2.12

0.27

-0.44

1.56

Resting HR

0.69

-0.07

6.68

0.50

-0.60

5.38

0.01

-0.43

0.44

BMI
Resting SBP

Total Cholesterol**

LDL

-0.32

-1.15

0.34

HDL

-0.06

-1.60

1.25

0.38

-2.05

5.89

.52

-1.32

10.07

Resting DBP
Perceived Stress
F-statistic for linear model

F20,7 = 2.65

F17,10 = 7.90

*p < 0.05. Abbreviations: 95 CI = confidence intervals; ApoE apolipoprotein e4 allele; B = standardized beta value from linear model; BMI = body mass index,
LL = Lower Level; UL= upper limit; QoL = Quality of life; cog. Dec. = cognitive decline; SBP = systolic blood pressure; DBP = Diastolic Blood Pressure;
TRG = triglycerides; GLU = Glucose; HR = Heart rate; LDL = low-density lipoprotein; HDL = High density lipoprotein.
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Chapter 5: Discussion
The first aim of this study was to examine if higher physical function clusters would
produce better cognitive scores than lower physical function cluster. To my knowledge, this is
the first study to examine physical function variables clustered together and examining the
cognitive differences between each cluster. My a priori hypothesis predicted higher physical
function cluster would display higher cognitive domain scores compared to lower physical
function clusters. My hypotheses was supported; higher physical function exhibited better global
cognitive scores and other cognitive domains than the lower clusters. Moreover, visuospatial
domain scores, attention tests, and delayed memory recall performance were significantly better
in the higher physical function cluster (Cluster 1) compared to lower physical functional clusters
(Cluster 2 and 3). Additionally, both higher functioning clusters exhibited better scores on
executive functioning and associative learning digital tasks than the lower functioning clusters.
Lastly, there were no significant differences identified in blood biomarkers between clusters.
The second aim of this study was to examine if ApoE ε4 carriers would mitigate physical
activity benefits among physically active individuals. My a priori hypothesis predicted ApoE ε4
carriers physical active (>50% on IPAQ) and inactive individuals (<50% on IPAQ) would have
lower cognitive scores and worse metabolic data than ApoE ε4 non-carriers. My hypotheses was
not supported; ApoE ε4 carriers that were physically active had lower BMI compared to the
ApoE ε4 carriers who were physically inactive. In addition, there was a trend towards
significance for lower triglycerides levels among ApoE ε4 carriers that were physically active
compared to ApoE ε4 carriers who were physically inactive, the reverse trend was observed in
non-carriers. ApoE ε4 carriers had significantly lower resting HR than non-carriers. Moreover,
ApoE ε4 carriers had significantly higher language scores than non-carriers. While, physically
inactive individuals showed higher global cognitive scores than physically active. Additionally,
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physically inactive individuals had higher associative learning scores. But, ApoE ε4 non-carriers
were trending towards significantly better scores on the associative memory task.
My final aim of the study was to evaluate the relationship between p-tau217 and
metabolic and behavioral risk factors. My a priori hypothesis suggested metabolic risk factors
and subjective cognitive decline will be associated with greater likelihood of elevated p-tau217
plasma levels. Both models retained the null hypothesis, metabolic and behavioral factors could
not predict p-tau217 values. My hypotheses was not supported but more research is needed
because the model was underpowered. But, women and higher BMI values were significant
correlations with elevated p-tau217. Since both models were underpowered, additional
participants are needed to examine these potential relationships.
My exploratory analyses showed that greater physical function clusters were associated
with greater global cognitive functioning. Physical activity and exercise studies have shown men
and women who are active in mid and late life are at lower risk for global cognitive decline
(Barnes et al., 2003; Hagan et al., 2016; Kirk-Sanchez & McGough, 2013; Weuve et al., 2004).
Although some of these investigations were longitudinal, researchers found that higher walking
levels and average metabolic equivalents have greater cognitive benefits and neuroprotection.
Moreover, our study found that executive functioning and delayed memory tasks were greater for
the higher physical function cluster compared to the lowest physical functioning cluster. The
Doetinchem Cohort Study exhibited the similar results with 6-11 year follow-up analyses
(Angevaren et al., 2007). Researchers found that the intensity and variation of physical activities
was positively associated with processing speed, memory, mental flexibility, and overall
cognitive function, interestingly duration was not associated with better cognitive functioning.

40
Likewise, a cross-sectional study found greater executive functioning among older men and
women with higher physical activity and greater energy expenditure rates (Bixby et al., 2007).
Similarly, this current study showed our highest cluster exhibiting greater muscular
fitness (handgrip and lower body power) values than the lowest. Previous investigations indicate
that higher handgrip values are associated with executive function, attention, memory, and
overall cognition, this was seen in this current study (Buchman, Boyle, et al., 2007; Buchman,
Wilson, et al., 2007; Rand & Eng, 2011). Moreover, higher physical function clusters showed
higher lower body power and velocity values as well. My results are similar to previous literature
in that higher muscular power and velocity scores had strong relationships with overall cognition
and executive function scores (Cherup et al., 2018; Petrella, 2004; Yoon et al., 2017). To my
knowledge, there are no studies examining lower body muscular power variables clustered
together, in aging adults, effect on cognition. Results will add to the literature and should be
explored more due to the neural component of power and velocity. Additionally, higher dual-task
velocity and fast walking speeds are associated with normal cognitive functioning (Gills et al.,
2020; Glenn et al., 2015; Gray et al., 2021). While cognitive differences were found between
clusters, there were no differences in blood and metabolic markers between the groups. Higher
physical functioning and more physically active groups usually have better metabolic profiles
than lower active groups (American College of Sports Medicine, 2018), but this is a specific
population at higher risk for cognitive decline. The requirements for this study were that
participants were overweight/obese, higher cholesterol, blood pressure, etc. So, the study design
deterred heterogeneity in the dataset among metabolic and blood biomarker profiles. Despite the
lack of blood and metabolic biomarker difference, participants with higher physical function
variables exhibited better cognitive outcomes. Combining these variables into physical function
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clusters may be a more efficient way of evaluating cognitive decline. Practitioners could use
these techniques to measure decline; however, more research completed is warranted to
understand cut-off values for normal cognitive function without increased risk compared to
individual’s at-risk and individuals with significant decline; as well as comparison to early
biomarker data.
Factoring in genetics with biomarker data, participants showed mixed results similar to
the literature (Colovati et al., 2021; Stringa et al., 2020). Physically active ApoE carriers showed
lower BMI and triglyceride (TRG) levels which may indicate that despite carrying the ApoE ε4
gene, physical activity is still protective in metabolic/biomarker data. However, previous data
have demonstrated higher TC and LDL, but not TRG, in ApoE carriers than non-carriers (Wang
et al., 2020). But, Wu and Colleagues (2016), found in a Taiwanese population that higher creactive protein levels were associated with higher TRG levels in ApoE carriers compared to
non-carriers (Wu et al., 2016). The data shown in this current study suggest that higher physical
activity levels may have a protective effect on ApoE carriers’ metabolic profiles. Further analysis
is needed to determine if inflammation plays a role in TRG levels in at-risk individuals.
Moreover, carriers also had higher language scores than non-carriers, but no interactions were
observed in cognitive data when controlling for age, sex, and education. However, previous
longitudinal studies and interventions have shown that physically active ApoE carriers have
better cognitive performance than inactive ApoE carriers (Ferrari et al., 2013; Jensen et al., 2019;
Shih et al., 2018; Smith et al., 2016; Solomon et al., 2018). Furthermore, physically active ApoE
carriers may curb their risk for dementia (Ferrari et al., 2013). A larger sample size is needed to
understand true differences in cognitive and metabolic data between ApoE and exercise. Also, an
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objective measure to examine physical activity would be a better method delineating accurate
interactions between physical activity and genetics.
Lastly, the underpowered model did not predict p-tau 217 levels. However, associations
were noticed with p-tau217. Higher BMI and sex were related to increased p-tau217 values.
These results contradictory to the literature on BMI and cognition since being overweight is
neuroprotective over time (Sun et al., 2020). Tracking this interaction longitudinally may be
useful when trying to identify if higher BMI is a risk factor for p-tau217. Moreover, women had
higher p-tau217 values than men which corresponds with previous investigations where women
have a higher likelihood of AD than men (Brookmeyer et al., 2011). While the survey results do
not coincide with the cognitive decline and ADRD literature, a larger sample size may reveal
significant correlations with p-tau217 and behavioral data. A recent investigation found that
higher quality of life predicted reduced risk of cognitive decline and dementia over time (Phyo et
al., 2021). Moreover, several additional studies found that quality of life was associated
longitudinal subjective cognitive decline and MCI (Pusswald et al., 2015; Roehr et al., 2017).
Additionally, this current investigation found no significant association between subjective
cognitive decline and p-tau217 values. Subjective cognitive decline and AD biomarker elevation
are indicators of stage 1 of cognitive decline outlined by the National Institute of Aging (Jessen
et al., 2014). Moreover, lower loneliness scores were not associated with higher p-tau217 plasma
values. Previous findings suggest loneliness or lack of social interaction is associated with a 40%
increased risk for dementia (Sutin et al., 2020). Moreover, lower sleep quality was not associated
with elevated p-tau217 in this current study. But, previous investigations have linked sleep
deprivation to elevated p-tau CSF levels (Barthélemy et al., 2020). While several of these
current independent variables may not be linked to p-tau217 in this study, more research is
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needed to evaluate their relationship. This model was underpowered because of the low sample
size due to ELISA detection range being too low to detect unimpaired individual’s p-tau217
levels. The average unimpaired individual is 1.9 pg/mL but the detection range lower end on the
ELISA kit used was 3.0 pg/mL (Palmqvist et al., 2021). Further research is needed to draw
complete conclusions in these relationships. If relationships are found and substantiated through
longitudinal studies and larger sample sizes, this provides insights to specific mechanisms that
can be targeted to reduce elevated plasma p-tau217.
This current investigation had several limitations due to the sample and sample size. The
sample was mainly Caucasian Americans which limits the generalizability of the results.
Heterogeneity in different populations may change current results from this study due to
education, genetics, and other social determinants of health. Moreover, this study sample size
hindered the conclusions that could be made from the physical activity, biomarker, and genetic
results. More robust sample size should be used to examine each variable on cognition. Also,
convenience sampling was used to find participants for this current study which limits
generalizability of the study. Lastly, cross-sectional data were used to evaluate these current
findings which hinders the conclusions that can be made because it only examines a single time
point. These findings would have to be measured longitudinally to confirm conclusions.
This is the first study examining cognitive differences among clustered physical function
variables. Current data suggests evaluating cognition through physical function/exercise
variables clustered together could provide a more efficient way of evaluating exercise on
cognition. Cluster 1 surpassed the minimal clinically important differences of >3.3 against both
cluster 2 and cluster 3 (Kivipelto et al., 2013). This indicates the value in cluster physical
function variables instead of examining a singular domain of physical fitness, each domain and
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measures of mobility can be grouped together. More research is needed on a larger scale to
incorporate genetics into the equation to determine if higher functioning cluster values can offset
genetic risk variants. This is a prospective method of evaluating cognitive decline that is less
invasive and cost-efficient. Also, significant associations were noticed between BMI, gender,
and p-tau217. Further longitudinal and larger sample sizes are required to confirm relationships.
Identifying these particular risk factors can help health care practitioners target specific
mechanisms to mitigate cognitive decline.
In conclusion, the results of this current study showed that clustering individuals by
physical function variables can discriminate global cognitive functioning. Moreover, it
delineated differences in spatial, delayed memory, associative learning, and executive
functioning scores. Higher physical activity rates in ApoE carriers demonstrated to lower BMI
and triglyceride levels but no cognitive differences were identified between physical activity
levels and ApoE. Lastly, elevated p-tau217 levels were related to higher BMI and women.
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